GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BiVictriX Therapeutics PLC (LSE:BVX) » Definitions » Inventory-to-Revenue

BiVictriX Therapeutics (LSE:BVX) Inventory-to-Revenue : 0.00 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is BiVictriX Therapeutics Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BiVictriX Therapeutics's Average Total Inventories for the quarter that ended in Jun. 2024 was £0.00 Mil. BiVictriX Therapeutics's Revenue for the six months ended in Jun. 2024 was £0.00 Mil.

BiVictriX Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2024 stayed the same from Dec. 2023 (0.00) to Dec. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.


BiVictriX Therapeutics Inventory-to-Revenue Historical Data

The historical data trend for BiVictriX Therapeutics's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BiVictriX Therapeutics Inventory-to-Revenue Chart

BiVictriX Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory-to-Revenue
Get a 7-Day Free Trial - - - - -

BiVictriX Therapeutics Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BiVictriX Therapeutics's Inventory-to-Revenue

For the Biotechnology subindustry, BiVictriX Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BiVictriX Therapeutics's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BiVictriX Therapeutics's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where BiVictriX Therapeutics's Inventory-to-Revenue falls into.



BiVictriX Therapeutics Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BiVictriX Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (A: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=N/A

BiVictriX Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue (Q: Jun. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Jun. 2024 )) / count ) / Revenue (Q: Jun. 2024 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BiVictriX Therapeutics  (LSE:BVX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BiVictriX Therapeutics's Days Inventory for the six months ended in Jun. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2024 )/Cost of Goods Sold (Q: Jun. 2024 )*Days in Period
=0/0*365 / 2
=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BiVictriX Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2024 ) / Average Total Inventories (Q: Jun. 2024 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BiVictriX Therapeutics Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of BiVictriX Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BiVictriX Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Alderley Edge, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG
BiVictriX Therapeutics PLC is a drug development company. It has developed its proprietary Bi-Cygni technology which utilizes Antibody Drug Conjugates for the treatment of various cancers including Acute Myeloid Leukaemia. The Group has one reportable segment, being the development of pharmaceutical products within the United Kingdom.

BiVictriX Therapeutics Headlines

No Headlines